These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26686247)

  • 1. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials.
    le Coutre PD; Hughes TP; Mahon FX; Kim DW; Steegmann JL; Shah NP; Gooden K; Wallis N; Cortes JE
    Leukemia; 2016 Jul; 30(7):1593-6. PubMed ID: 26686247
    [No Abstract]   [Full Text] [Related]  

  • 2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Fujii Y; Amano M; Seriu T
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):159-67. PubMed ID: 19749489
    [No Abstract]   [Full Text] [Related]  

  • 5. Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.
    Prestes DP; Arbona E; Nevett-Fernandez A; Woolley AE; Ho VT; Koo S; Baden LR; Koreth J; Hammond SP; Issa NC; Marty FM
    Clin Infect Dis; 2017 Aug; 65(3):510-513. PubMed ID: 28419210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
    Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G
    Haematologica; 2007 Mar; 92(3):401-4. PubMed ID: 17339191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe peripheral arterial disease during nilotinib therapy.
    Le Coutre P; Rea D; Abruzzese E; Dombret H; Trawinska MM; Herndlhofer S; Dörken B; Valent P
    J Natl Cancer Inst; 2011 Sep; 103(17):1347-8. PubMed ID: 21813414
    [No Abstract]   [Full Text] [Related]  

  • 9. Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
    Santos FP; Rodrigues M; Mac-Donald Bley do Nascimento C; Kerbauy FR; Ribeiro AA; Mauro Kutner J; Hamerschlak N
    Cytotherapy; 2010; 12(1):113-5. PubMed ID: 19878083
    [No Abstract]   [Full Text] [Related]  

  • 10. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
    Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
    Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between Dasatinib-induced Pulmonary Hypertension and Drug Dose.
    Kubota K; Imai Y; Oh I; Ueno S; Kanda Y; Kario K
    Intern Med; 2022 Aug; 61(15):2263-2271. PubMed ID: 35022343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib-induced Chylothorax in Chronic Myelogenous Leukemia in Pediatric Patient: Report of a Case and Review of Literature.
    Hickman K; Diaz E; Graham R; Adams R; Ngwube A
    J Pediatr Hematol Oncol; 2020 Oct; 42(7):e665-e667. PubMed ID: 31688632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
    Edahiro Y; Takaku T; Konishi H; Tsukune Y; Fujioka I; Takasu K; Gotoh A; Daida H; Komatsu N
    Rinsho Ketsueki; 2017; 58(11):2213-2218. PubMed ID: 29212971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial pneumonitis associated with dasatinib: two case reports and literature review.
    Ito Y; Tanigawa M; Iwamoto K; Nigi A; Itani H; Kondo S; Tokui T; Usui E; Tamaki S
    Respir Investig; 2019 Sep; 57(5):506-509. PubMed ID: 31311724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia.
    Yim E; Choi YG; Nam YJ; Lee J; Kim JA
    Korean J Intern Med; 2018 Mar; 33(2):446-448. PubMed ID: 26961484
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
    McGrath K; Stein B; Kalhagen L; Leighton L
    Ann Allergy Asthma Immunol; 2017 Jul; 119(1):85-86. PubMed ID: 28499700
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
    Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
    Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
    J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
    [No Abstract]   [Full Text] [Related]  

  • 19. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumocystis jiroveci pneumonia in patients receiving dasatinib treatment.
    Chang H; Hung YS; Chou WC
    Int J Infect Dis; 2014 Aug; 25():165-7. PubMed ID: 24932855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.